Cagrilintide

CAS No.: 1415456-99-3

Cagrilintide Chemical Structure

Molecular formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂

Molecular weight: 4408. 258

Patent period: —

Strengths: —

Injection: —

Oral tablets: —

Injection : —

Get in touch Download

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Biological Activity

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Chemical Properties

ACTIONS	—
CAS NO.	1415456-99-3
FORMULA	C₁₉₄H₃₁₂N₅₄O₅₉S₂
M. WT	4408. 258
PURITY	—
SYNONYMS	—
STORAGE	—

Online Inquiry

Obesity

The number of global obesity in 2020 reached 1. 211 billion, an increase of 58 million people from 2019, an increase of 5. 04% year -on -year.In 2020, the number of obesity in China reached 220 million people, an increase of 1. 10 billion from 2019, an increase of 4. 77%year -on -year.

Other Drug Peptide More+

Tirzepatide new

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined .
Semaglutide new

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.
Retatrutide new

Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR) , glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) . It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5. 79, 0. 0643 and 0. 775nM, respectively. Retarutide can be used for obesity research.
Cagrilintide new

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Product Catalog

Cagrilintide

GUIZHOU MTPEPTIDES BIOTECHNOLOGY CO., LTD